Pacific Biosciences (PACB) AI Stock Analysis

• Market Cap: $401.66M
• Dividend Yield: N/A
• Average Volume (3M): 6.38M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: -10.72%
• EPS Growth: -16.00%
• Country: US
• Employees: 575
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.13
• Shares Outstanding: 301,998,300
• 10 Day Avg. Volume: 6,390,212
• 30 Day Avg. Volume: 6,384,548
• PEG Ratio: -0.02
• Price to Book (P/B): 104.87
• Price to Sales (P/S): 3.51
• P/FCF Ratio: -4.92
• Enterprise Value/Market Cap: 2.75
• Enterprise Value/Revenue: 6.92
• Enterprise Value/Gross Profit: 24.52
• Enterprise Value/Ebitda: -6.90
• 1Y Price Target: $2.38
• Price Target Upside: 78.95% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5
• EPS Forecast (FY): -0.52
• Revenue Forecast (FY): $174.19M

• Rating: 46 Neutral
• Price Target: $1.50 ▲(12.78% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is primarily constrained by weak financial performance (deep losses, ongoing cash burn, and a significantly weakened balance sheet). Technicals also remain bearish with the stock trading below key moving averages. Earnings-call commentary provides some offset via consumables-led momentum, improving margins, and a path toward better cash burn, but guidance remains modest and demand/cost risks persist.

Positive Factors

Consumables Recurring Revenue

A growing, record consumables business strengthens the razor/razor-blade model: recurring reagent and SMRT cell sales drive predictable revenue and higher lifetime value per installed system. Durable consumables growth supports revenue stability, margin leverage and funding runway independent of instrument cycles.

Gross Margin Expansion

Sustained gross-margin improvement reflects a higher-consumables mix, cost reductions, and product/chemistry gains (e.g., SparkNex). Higher gross margins are structurally positive for profitability potential because consumables are higher-margin and scale with installed base, improving long-term operating leverage.

Installed Base & Platform Momentum

Growing installed base increases consumable pull-through and creates commercial flywheel. New-to-PacBio Vega placements (~65% of Vega 2025) expand addressable market and HiFi adoption, creating a durable foundation for recurring revenue and broader clinical/population sequencing penetration over time.

Negative Factors

Weakened Capitalization

A materially weakened balance sheet with equity near zero and elevated leverage reduces financial flexibility and raises refinancing and dilution risk. Limited capitalization constrains the company's ability to fund R&D, scale commercial efforts, or absorb shocks without dilutive financing or restrictive terms.

Persistent Cash Burn

Consistent negative operating and free cash flow create ongoing funding needs. Even with improved burn rates, sustained outflows mean management must secure financing or further cuts, which can limit long-term investment in product launches, commercial expansion, and R&D required to capture larger market opportunities.

Ongoing Losses & Instrument Headwinds

Large recurring losses and declining instrument sales weaken the growth engine for future consumables and make profitability elusive. Academic capital spending headwinds and ASP/discount pressure on placements can slow installed-base growth and compress long-term margin and revenue trajectory if not reversed.

Pacific Biosciences Business Overview & Revenue Model

Company Description

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

How the Company Makes Money

Pacific Biosciences generates revenue primarily through the sale of its DNA sequencing systems, consumables, and related services. The company's revenue model includes the direct sale of sequencing instruments, reagents, and flow cells used in the sequencing process, as well as service contracts for maintenance and support. Additionally, PACB earns revenue from collaborations and partnerships with academic institutions, pharmaceutical companies, and research organizations, which often include grants and funding for joint projects. The increasing demand for genomic data in both research and clinical settings, along with strategic partnerships that enhance its market reach, contribute significantly to its earnings.

Pacific Biosciences Financial Statement Overview

Summary

Multi-year revenue growth is overshadowed by sharply deteriorated profitability, persistent large net losses, sustained cash burn, and a materially weakened 2025 balance sheet with equity collapsing relative to debt—raising dilution/refinancing risk despite some operational improvements.

Income Statement

Revenue has grown over the long run (from ~$79M in 2020 to ~$160M in 2025) with a modest pickup in 2025, but profitability has deteriorated sharply. Gross margin has compressed versus earlier years and the company is deeply unprofitable, with very large operating and net losses in 2024–2025 (net margin meaningfully negative). Overall, the top-line trajectory is positive, but the cost structure and loss profile are the dominant weakness.

Balance Sheet

Leverage and equity trends are the key concern. Total debt remains high while stockholders’ equity fell from hundreds of millions historically to near-zero in 2025, driving an extremely elevated debt-to-equity level and severely negative returns on equity. Compared with prior years (when leverage was moderate), the 2025 balance sheet shows a major deterioration in capitalization and financial flexibility.

Cash Flow

Cash generation is consistently negative: operating cash flow and free cash flow are materially outflowing in most years and worsened again in 2025 versus 2024. While free cash flow has generally tracked net losses (i.e., cash burn is broadly consistent with reported losses rather than being worse), the magnitude and persistence of cash burn increases funding risk without a clear near-term inflection.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	160.00M	154.01M	200.52M	128.30M	130.51M
Gross Profit	50.67M	37.28M	52.78M	49.03M	58.86M
EBITDA	-34.20M	-242.77M	-271.13M	-282.24M	-250.76M
Net Income	-546.38M	-309.85M	-306.74M	-314.25M	-181.22M
Balance Sheet
Total Assets	784.08M	1.26B	1.75B	1.77B	2.01B
Cash, Cash Equivalents and Short-Term Investments	279.51M	389.93M	631.42M	772.32M	1.04B
Total Debt	759.46M	672.43M	933.93M	948.48M	955.36M
Total Liabilities	778.73M	753.85M	1.04B	1.20B	1.22B
Stockholders Equity	5.35M	506.59M	701.30M	562.90M	790.99M
Cash Flow
Free Cash Flow	-113.92M	-212.25M	-275.39M	-280.14M	-117.11M
Operating Cash Flow	-111.21M	-206.06M	-266.55M	-263.21M	-111.18M
Investing Cash Flow	115.45M	124.00M	4.60M	116.08M	-678.53M
Financing Cash Flow	3.43M	-42.99M	116.27M	9.62M	1.17B

Pacific Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PACB, the sentiment is Negative. The current price of 1.33 is below the 20-day moving average (MA) of 1.54, below the 50-day MA of 1.90, and below the 200-day MA of 1.65, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 33.79 is Neutral, neither overbought nor oversold. The STOCH value of 10.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PACB.

Pacific Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MASS	58 Neutral	$226.90M	9.76	13.25%	―	4.49%	3.61%
BFLY	55 Neutral	$967.60M	-12.19	-35.34%	―	16.04%	28.91%
CTKB	52 Neutral	$515.49M	-9.70	-18.01%	―	-2.18%	-30.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OM	51 Neutral	$59.54M	-0.69	-54.99%	―	4.65%	68.71%
NPCE	47 Neutral	$474.37M	-23.54	-105.67%	―	24.08%	24.08%
PACB	46 Neutral	$401.66M	-1.03	-1123.27%	―	-10.72%	-16.00%

Pacific Biosciences Corporate Events

Pacific Biosciences Secures Key Patent License, Ends Litigation

On March 2, 2026, Pacific Biosciences said Chief Accounting Officer Michele Farmer had resigned effective March 21, 2026, to pursue another opportunity, with the company emphasizing there was no disagreement over accounting or other practices and no severance to be paid. Chief Financial Officer Jim R. Gibson, who has held that role since 2025, will add the responsibilities of principal accounting officer without a change in compensation.

On March 5, 2026, the company entered a binding term sheet with Personal Genomics of Taiwan, Inc. that grants PacBio a worldwide, royalty-free, non-exclusive license to a key U.S. patent family and a five-and-a-half-year covenant not to sue, in exchange for fixed payments potentially totaling up to $23 million through 2029. The deal will end ongoing litigation between the parties, convert legal uncertainty into defined, time-bound protection, and is intended to support PacBio’s long-read sequencing growth strategy and provide greater operational certainty for its commercial ecosystem.

The most recent analyst rating on (PACB) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.

PacBio Adds AI-Driven Drug Discovery Leader to Board

On March 3, 2026, PacBio’s board of directors expanded to ten members and appointed Christopher Gibson, Ph.D., co-founder and chairman of AI-driven drug discovery company Recursion, as a Class I director with a term running until the 2026 annual meeting of stockholders. Effective that date, he also joined the Science and Technology Committee and became eligible for the company’s standard non-employee director compensation and indemnification, with PacBio confirming there are no related-party or family relationships tied to his appointment.

In a March 5, 2026 announcement, PacBio highlighted Gibson’s track record in integrating large-scale biological data, automation, and machine learning to industrialize drug discovery as a key strategic asset as the company develops data tools to maximize the value of its HiFi long-read sequencing. The board move underscores PacBio’s intention to deepen its capabilities at the intersection of sequencing, computation, and AI-driven analytics, signaling a push to strengthen its competitive position in data-intensive genomics and support its long-term vision in data-driven biological discovery for stakeholders across research and healthcare.

The most recent analyst rating on (PACB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.

Pacific Biosciences Announces Interim Leadership Role Realignment

On February 3, 2026, Pacific Biosciences of California, Inc. reported that, effective January 28, 2026, Chief Operating Officer Mark Van Oene had on an interim basis taken over responsibility for the company’s sales and customer support organizations, duties previously overseen by President and Chief Executive Officer Christian Henry. In turn, Henry had on an interim basis assumed oversight of the company’s operations and research and development organizations from Van Oene, with both executives retaining their other core responsibilities and experiencing no changes to their titles or compensation, signaling an internal rebalancing of leadership roles rather than a broader strategic or structural overhaul.

The most recent analyst rating on (PACB) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.

Pacific Biosciences Strengthens Balance Sheet via Asset Sale

On January 30, 2026, Pacific Biosciences of California completed the sale of certain intellectual property and other assets tied to its short-read DNA sequencing technology, including clustering, sequencing reagent and detection technologies, to Illumina Cambridge Limited for $50 million in cash plus the assumption of certain liabilities. After directing 4% of the proceeds to former equity holders of Apton Biosystems in connection with waived milestone obligations from PacBio’s August 2023 acquisition of Apton, the company realized approximately $48.1 million in net cash and received a non-exclusive license back to some of the divested intellectual property, a move that strengthens its balance sheet and clarifies its strategic positioning while reducing future Apton-related payment obligations. PacBio has issued unaudited pro forma financial statements to show the impact of the asset sale on its September 30, 2025 balance sheet and on its 2024 and year-to-date 2025 operating results, providing investors greater visibility into the company’s capital structure and post-transaction financial profile.

The most recent analyst rating on (PACB) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.

PacBio Announces Strong Preliminary Q4 and 2025 Revenue

On January 12, 2026, PacBio reported preliminary unaudited results indicating that fourth-quarter 2025 revenue rose 14% year-on-year to approximately $44.6 million, while full-year 2025 revenue grew 4% to about $160.0 million, driven by strong uptake of its Revio and Vega sequencing systems and record consumables sales. The company also highlighted a sharp ramp in Vega placements, stable Revio pull-through, and a reduction in cash, cash equivalents, and investments to roughly $279.5 million from $389.9 million a year earlier, underscoring both growing traction in clinical sequencing applications and ongoing cash burn; management indicated that full audited 2025 results, which could differ materially from these preliminary figures, will be detailed when PacBio reports earnings in February and files its annual report.

The most recent analyst rating on (PACB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Pacific Biosciences stock, see the PACB Stock Forecast page.